1:10 PM
 | 
Mar 07, 2018
 |  BC Extra  |  Company News

FDA panel backs Blincyto in ALL subpopulation

FDA’s Oncologic Drugs Advisory Committee voted 8-4 that data from a Phase II trial showed the benefits of Blincyto blinatumomab from Amgen Inc. (NASDAQ:AMGN) outweigh its risks in treating minimal residual disease (MRD)-positive B cell precursor...

Read the full 156 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >